A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Trial Profile

A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 2
  • Sponsors Rempex Pharmaceuticals; The Medicines Company
  • Most Recent Events

    • 05 Oct 2017 Results presented in The Medicines Company media release.
    • 30 Aug 2017 According to The Medicines Company media release, data from the TANGO clinical program along with this trial will be presented at IDWeek 2017 in October.
    • 06 Aug 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top